High-Intensity Focus Ultrasound for Prostate Cancer
Author Information
Author(s): Yang Che-Hsueh, Barbulescu Daniela-Viviana, Marian Lucian, Tung Min-Che, Ou Yen-Chuan, Wu Chi-Hsiang
Hypothesis
This study aims to summarize the current clinical trials of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.
Conclusion
Whole-gland ablation is recommended as the general approach for prostate cancer treatment, as it provides better outcomes compared to focal and hemigland ablation.
Supporting Evidence
- HIFU may offer superior functional outcomes, particularly in continence recovery, compared to radical prostatectomy and radiation therapy.
- Focal and hemigland ablations carry a risk of residual significant cancer.
- Post-HIFU monitoring is recommended using 3T MRI with biopsy at 6 to 12 months.
Takeaway
Doctors are looking at a special ultrasound treatment for prostate cancer that might help men keep their ability to control their pee and have erections after treatment.
Methodology
The study reviewed clinical trials from major databases including PubMed, MEDLINE, Scopus, and EMBASE.
Potential Biases
The literature suffers from heterogeneous study endpoints and inconsistent surveillance methods.
Limitations
The oncological efficacy of HIFU remains inadequately supported by high-quality studies, and there is a risk of residual significant cancer.
Participant Demographics
80% to 90% of included patients were categorized as low- or intermediate-risk groups.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website